StockData
Mereo BioPharma Group plc logo

Mereo BioPharma Group plc (MREO) stock

MREONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 1/30
$0.29+0.01 (+5.39%)

Close on Nov 18, 2026Market cap $46.20MP/E –Yield –

Mereo BioPharma profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Mereo BioPharma's profit margin for the twelve months ending Dec 31, 2025 was -8375.6%. For fiscal 2025 it was -8375.6%, against -294.7% the year before.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-8375.6%−8080.9
FY2023Dec 31, 2023-294.7%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 2026-732.9%–
Q2 FY2025Jun 30, 2025-2923.2%–
Q4 FY2023Dec 31, 2023-910.9%–
Q2 FY2023Jun 30, 2023-19.5%–

More Mereo BioPharma figures

See a number that looks wrong?